Humacyte Inc HUMA.OQ HUMA.O is expected to show a rise in quarterly revenue when it reports results on August 11 for the period ending June 30 2025
The Durham North Carolina-based company is expected to report revenue of $1.003 million, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Humacyte Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Humacyte Inc is $6.50, about 62% above its last closing price of $2.47
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.18 | -0.19 | 0.28 | Beat | 247.4 |
Dec. 31 2025 | -0.27 | -0.25 | -0.16 | Beat | 36 |
Sep. 30 2024 | -0.25 | -0.25 | -0.33 | Missed | -32.8 |
Jun. 30 2024 | -0.24 | -0.24 | -0.48 | Missed | -101.7 |
Mar. 31 2024 | -0.22 | -0.22 | -0.29 | Missed | -28.9 |
Dec. 31 2023 | -0.25 | -0.24 | -0.24 | Met | 2 |
Sep. 30 2023 | -0.25 | -0.25 | -0.25 | Met | 1.3 |
Jun. 30 2023 | -0.22 | -0.22 | -0.22 | Met | -0.1 |
This summary was machine generated August 8 at 14:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)